Zhuhai Hengqin Guoyan Pharmaceutical Technology

Zhuhai Hengqin Guoyan Pharmaceutical Technology is a Chinese pharmaceutical company founded in 2023 and operating as a wholly-owned subsidiary of Guobiao Pharmaceutical Group. Headquartered in the Hengqin New Area of Zhuhai, Guangdong, the company has obtained a Type B Drug Manufacturing License, establishing itself as a Marketing Authorization Holder (MAH). It focuses on drug research and development, quality testing, and the commercial translation of pharmaceutical products, particularly liquid preparations and injections. Its product pipeline includes small molecule generic and improved drugs such as ketorolac tromethamine injection, amisulpride oral solution, bromhexine hydrochloride oral solution, and a bowel-cleansing electrolyte solution. By leveraging the resources of its parent group and collaborating with contract manufacturing organizations, the company aims to deliver high-quality and accessible healthcare solutions to the Chinese market.